Investment Analysts’ Weekly Ratings Changes for Monte Rosa Therapeutics (GLUE)

Several brokerages have updated their recommendations and price targets on shares of Monte Rosa Therapeutics (NASDAQ: GLUE) in the last few weeks:

• 8/11/2026 – Monte Rosa Therapeutics was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
• 8/7/2026 – Monte Rosa Therapeutics had its price target lowered by Guggenheim from $35.00 to $28.00. They now have a “buy” rating on the stock.
• 8/7/2026 – Monte Rosa Therapeutics had its price target lowered by JPMorgan Chase & Co. from $31.00 to $27.00. They now have an “overweight” rating on the stock.
• 8/7/2026 – Monte Rosa Therapeutics had its price target lowered by Wells Fargo & Company from $29.00 to $27.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Monte Rosa Therapeutics was upgraded by Zacks Research from “strong sell” to “hold”.
• 8/3/2026 – Monte Rosa Therapeutics had its price target lowered by Wedbush from $37.00 to $27.00. They now have an “outperform” rating on the stock.
• 7/28/2026 – Monte Rosa Therapeutics was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
• 7/27/2026 – Monte Rosa Therapeutics had its “buy” rating reaffirmed by Jefferies Financial Group Inc..
• 7/27/2026 – Monte Rosa Therapeutics was given a new $25.00 price target by Jefferies Financial Group Inc..
• 7/6/2026 – Monte Rosa Therapeutics was downgraded by Zacks Research from “hold” to “strong sell”.
• 6/30/2026 – Monte Rosa Therapeutics had its price target raised by Guggenheim from $30.00 to $35.00. They now have a “buy” rating on the stock.
• 6/30/2026 – Monte Rosa Therapeutics had its price target raised by Guggenheim from $30.00 to $35.00. They now have a “buy” rating on the stock.

Insider Activity

In other news, Director Anthony M. Manning sold 10,000 shares of the stock in a transaction on Monday, June 29th. The shares were sold at an average price of $23.11, for a total value of $231,100.00. Following the sale, the director owned 10,000 shares of the company’s stock, valued at approximately $231,100. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Jennifer Champoux sold 2,176 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $19.00, for a total transaction of $41,344.00. Following the completion of the sale, the chief operating officer owned 62,371 shares of the company’s stock, valued at $1,185,049. This trade represents a 3.37% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 81,778 shares of company stock valued at $1,768,581 over the last ninety days. 6.40% of the stock is owned by corporate insiders.

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.